Recursion Pharmaceuticals
PublicRecursion Pharmaceuticals is now publicly traded
The data on this page reflects Recursion Pharmaceuticals's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Went Public
Apr 16, 2021
Last Round
Follow-on Offering
Jun 26, 2024
Est. Valuation at Exit
$1.74B
Total Funding Raised
$1.14B
Company Overview
Recursion Pharmaceuticals is a biotechnology company that industrializes drug discovery by integrating technological innovations across biology, chemistry, automation, data science, and engineering.
Sector
Biotech
AI Layer
Infrastructure
Keywords
Recursion Pharmaceuticals Comparables
Compare Recursion Pharmaceuticals with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Valo Health | 87% | |
| Insilico Medicine | 87% | |
| Insitro | 86% |
For institutional investors. Book with your work email.
Recursion Pharmaceuticals Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Follow-on Offering | Jun 26, 2024 | ||||
| IPO | Apr 16, 2021 | ||||
| Series D | Sep 9, 2020 | ||||
| Series C | Jul 15, 2019 | ||||
| Series B | Oct 4, 2017 | ||||
Series A | Oct 3, 2016 |
For institutional investors. Book with your work email.
Recursion Pharmaceuticals Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Human Capital | Series D |
| Scottish Mortgage Investment Trust | Series C |
| Advantage Capital | Series D, Series B |
| Intermountain Ventures | Series D, Series C |
| Lux Capital | Series D, Series C, Series B, Series A |
| Catalio Capital Management | Series D |
| Obvious Ventures | Series D, Series C, Series A, Series B |
For institutional investors. Book with your work email.
Recursion Pharmaceuticals Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.